ClinicalTrials.gg
Not yet recruitingNCT07850856HFNC COPDUpdated Sep 30, 2026

HFNC During Bronchoscopy in COPD Patients

An interventional study of group N used traditional nasal cannula for oxygen inhalation and Group HFNC used nasal high-flow oxygen inhalation. in COPD, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · The First Affiliated Hospital of Guangzhou Medical University.

Planned enrollment
Largest of 16
1,000 · median 25
Started
2026
with 2 others
No phase
13 of 19
3 open now
Registered
19th of 19
by date

Among the 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 19th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

Bronchoscopy diagnosis and treatment is highly irritating, and the effect of local topical anesthesia is poor; the airway is shared; and COPD patients have low oxygen reserves due to impaired lung function. At present, clinical anesthesia generally uses nasal cannula for oxygen inhalation. If the anesthesia is too shallow, it may cause airway spasm, and if the anesthesia is too deep, it will inhibit breathing and lead to hypoxia. Hypoxemia has been reported in 66% of COPD patients undergoing sedation for bronchoscopy. Therefore, solving hypoxia is the biggest problem in anesthesia for bronchoscopy diagnosis and treatment.

Read the detailed description

Bronchoscopy diagnosis and treatment is highly irritating, and local topical anesthesia has poor effect; deep sedation or intravenous anesthesia based on topical anesthesia is currently recommended; COPD patients have impaired lung function, and bronchoscopy diagnosis and treatment is accompanied by significant peri-anesthetic risks of hypoxemia. COPD patients are prone to hypoxemia due to the shared airway and sedative and analgesic drugs used to suppress breathing during bronchoscopy diagnosis and treatment. Therefore, solving hypoxia is the biggest problem for COPD patients during anesthesia during bronchoscopy. In recent years, studies have found that high-flow nasal oxygen therapy (HFNC) can significantly reduce the incidence of hypoxemia during anesthesia during bronchoscopy. However, very few studies have performed HFNC on patients with COPD.

03

Conditions studied

  • COPD

Keywords

  • HFNC
  • COPD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ,(ASA)Ⅰ ~ Ⅲ

Exclusion criteria

Exclusion Criteria:

  • to bronchoscopy or anesthesia, Nosebleeds
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    Group N

    Group N used traditional nasal cannula to inhale oxygen during anesthesia.

    Other: group N used traditional nasal cannula for oxygen inhalation

  • Experimental
    Group HFNC

    During anesthesia, the HFNC group used nasal high-flow oxygen inhalation

    Other: Group HFNC used nasal high-flow oxygen inhalation.

Interventions

  • Othergroup N used traditional nasal cannula for oxygen inhalation

    1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group(group N) and nasal cannula oxygen inhalation group(group HFNC).The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.

  • OtherGroup HFNC used nasal high-flow oxygen inhalation.

    1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group(group N) and nasal cannula oxygen inhalation group(group HFNC).The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.

06

What researchers measure

Primary outcomes

  1. pulse oximetry

    Blood oxygen saturation during anesthesia, record the duration and number of times below 90%

    Time frame: The entire anesthesia period during bronchoscopy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Upon completion of the study, de-identified individual participant data (IPD) and relevant supporting documents (e.g., study protocol, statistical analysis plan) will be shared upon reasonable request with researchers who provide a methodologically sound research proposal. Data will be made available starting 6 months after publication of the primary results and will remain available for 5 years. Requests must be submitted via [designated email or website], and a data use agreement must be signed.

Time frame: Beginning 6 months and ending 5 years following publication of primary results.

Access criteria: Researchers who provide a methodologically sound proposal. Proposals should be directed to [your email]. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 27 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2026
First posted
Sep 30, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850856
Responsible party
Liya Lu (deputy chief physician, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion